Data / Research funding / New York / Xylyx Bio, Inc.
Xylyx Bio, Inc.: 4 NIH awards ($6.5M), fiscal years 2021 to 2026
Xylyx Bio, Inc. in Brooklyn, NY is funded under 4 NIH awards ($6.5M) in the NIH and NSF award files, read 2026-11-03. NIH fiscal years 2021 to 2025; NSF fiscal years 2022 to 2026.
SpecStream is the live web data engine for teams and agents. It reads the NIH and NSF award files each time the agencies update them, and this page is that reading, joined to the open federal funding opportunities on Grants.gov. Ask for the awards you track by topic, organization or state and new awards arrive in your sheet, CRM, Slack or agent as the agencies publish them.
- UEI
- N2N9KL2Y52X1
- State
- New York
Awards
4 awards in the window.
| Award | Agency | Institute or division | Fiscal year | Amount in window | Start | End | Principal investigator | Source |
|---|
| Lung fibrosis modeling and compound testing platform using fibrotic lung ECM that recreates the fibrotic disease environment to improve predictiveness and accelerate anti-fibrotic drug development | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $2,389,178 | September 1, 2021 | February 28, 2024 | O'NEILL, JOHN DAVID | reporter.nih.gov |
| Translational development and clinical evaluation of a bioengineered human lung graft for clinical transplantation | NIH | National Heart, Lung, and Blood Institute | 2025 | $1,515,926 | September 8, 2025 | June 30, 2027 | O'NEILL, JOHN DAVID | reporter.nih.gov |
| Liver fibrosis cell-based assay platform: integrating patient-derived fibrotic liver ECM with primary stellate cells, Kupffer cells, and hepatocytes to accelerate anti-fibrotic drug development | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2024 to 2025 | $1,337,735 | September 1, 2024 | August 31, 2027 | O'NEILL, JOHN DAVID | reporter.nih.gov |
| Multi-organ metastatic breast cancer cell-based assay platform that models organotropic metastases using patient organoids in human tissue-derived ECMs to accelerate anti-metastatic drug development | NIH | National Cancer Institute | 2024 to 2025 | $1,262,024 | June 6, 2024 | May 31, 2027 | O'NEILL, JOHN DAVID | reporter.nih.gov |
Funding by fiscal year
| Fiscal year | NIH awards | NIH amount | NSF awards | NSF amount |
|---|
| 2025 | 3 | $3,450,061 | 0 | $0 |
| 2024 | 2 | $665,624 | 0 | $0 |
| 2023 | 1 | $1,140,722 | 0 | $0 |
| 2022 | 1 | $950,532 | 0 | $0 |
| 2021 | 1 | $297,924 | 0 | $0 |
Open federal funding opportunities
From Grants.gov: notices that funded awards in this table, and open notices on the same agency and assistance listing.
| Open opportunity | Number | Agency | Listing | Closes | Award ceiling | Why it matches |
|---|
| Emerging Global Leader Award (K43 Independent Clinical Trial Required) | PAR-24-295 | NIH | 93.838 | December 3, 2026 | Not listed | Same assistance listing 93.838 as 2 awards here |
| Emerging Global Leader Award (K43 Independent Clinical Trial Not Allowed) | PAR-24-296 | NIH | 93.838 | December 3, 2026 | Not listed | Same assistance listing 93.838 as 2 awards here |
| NIH Research Software Engineer (RSE) Award (R50 Clinical Trials Not Allowed) | RFA-OD-24-011 | NIH | 93.838 | December 4, 2026 | Not listed | Same assistance listing 93.838 as 2 awards here |
| Small Business Transition Grant for New Entrepreneurs (Parent R43/R44 Clinical Trial Optional) | PAR-27-039 | NIH | 93.838 | January 5, 2027 | Not listed | Same assistance listing 93.838 as 2 awards here |
| Small Business Transition Grant for New Entrepreneurs (Parent R41/R42 Clinical Trial Optional) | PAR-27-040 | NIH | 93.838 | January 5, 2027 | Not listed | Same assistance listing 93.838 as 2 awards here |
| Academic Research Enhancement Award (AREA) for Undergraduate-Focused Institutions (R15 Clinical Trial Required) | PAR-24-214 | NIH | 93.838 | January 7, 2027 | $375,000 | Same assistance listing 93.838 as 2 awards here |
| Intervention Research to Improve Native American Health (R01 Clinical Trial Optional) | PAR-25-379 | NIH | 93.838 | January 7, 2027 | Not listed | Same assistance listing 93.838 as 2 awards here |
| NHLBI Early Phase Clinical Trials for Therapeutics and/or Diagnostics for HLBS Disorders (R33 CT Required) | PAR-25-025 | NIH | 93.838 | February 3, 2027 | $1.5 million | Same assistance listing 93.838 as 2 awards here |
| NHLBI Early Phase Clinical Trials for Therapeutics and/or Diagnostics for HLBS Disorders (R61/R33 Clinical Trial Required) | PAR-25-026 | NIH | 93.838 | February 3, 2027 | Not listed | Same assistance listing 93.838 as 2 awards here |
| Multi-Site Investigator-Initiated Clinical Trials (Collaborative UG3/UH3 Clinical Trial Required) | PAR-27-125 | NIH | 93.838 | February 16, 2027 | Not listed | Same assistance listing 93.838 as 2 awards here |
| Continuation of the Cardiovascular Repository for-Type 1 Diabetes (CARE-T1D) Consortium U01 (Open Competition)- Research (U01, Clinical Trial Not Allowed) | RFA-DK-27-108 | NIH | 93.838 | March 10, 2027 | $500,000 | Same assistance listing 93.838 as 2 awards here |
| NHLBI Clinical Trial Pilot Studies (R34 Clinical Trial Optional) | PAR-25-032 | NIH | 93.838 | March 16, 2027 | Not listed | Same assistance listing 93.838 as 2 awards here |
| NIH, CDC and FDA Small Business Innovation Research Grant (Parent SBIR [R43/R44] Clinical Trial Optional) | PA-27-100 | NIH | 93.838 | April 5, 2027 | Not listed | Same assistance listing 93.838 as 2 awards here |
| NIH Small Business Technology Transfer Grant (Parent STTR [R41/R42] Clinical Trial Optional) | PA-27-102 | NIH | 93.838 | April 5, 2027 | Not listed | Same assistance listing 93.838 as 2 awards here |
| Short Courses on Innovative Methodologies and Approaches in the Behavioral and Social Sciences (R25 Clinical Trials Not Allowed) | RFA-OD-25-003 | NIH | 93.838 | April 9, 2027 | $200,000 | Same assistance listing 93.838 as 2 awards here |
| NHLBI Outstanding Investigator Award (OIA) (R35 Clinical Trial Optional) | RFA-HL-26-002 | NIH | 93.838 | April 28, 2027 | Not listed | Same assistance listing 93.838 as 2 awards here |
| NHLBI Emerging Investigator Award (EIA) (R35 Clinical Trial Optional) | RFA-HL-26-003 | NIH | 93.838 | April 28, 2027 | Not listed | Same assistance listing 93.838 as 2 awards here |
| Mentored Research Scientist Development Award (Parent K01 - Independent Clinical Trial Required) | PA-24-175 | NIH | 93.838 | May 7, 2027 | Not listed | Same assistance listing 93.838 as 2 awards here |
| Mentored Research Scientist Development Award (Parent K01 - Independent Clinical Trial Not Allowed) | PA-24-176 | NIH | 93.838 | May 7, 2027 | Not listed | Same assistance listing 93.838 as 2 awards here |
| Mentored Patient-Oriented Research Career Development Award (Parent K23 Independent Clinical Trial Not Allowed) | PA-24-185 | NIH | 93.838 | May 7, 2027 | Not listed | Same assistance listing 93.838 as 2 awards here |
Topics of its NIH awards
Updated November 3, 2026. Read from NIH RePORTER ExPORTER and NSF Award Search. Published by NIH and NSF as U.S. government data. NIH awards are fiscal years 2021 to 2025 (NIH files published to 2026-07-09); NSF awards are fiscal years 2022 to 2026 (NSF files published to 2026-11-02). NIH amounts are the total cost of each fiscal year in the window; NSF amounts are the funds obligated in the window. Organizations are matched on the UEI. Open opportunities come from Grants.gov and match on agency and assistance listing number, and on the notice number NIH prints on an award. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.